Sensitivity, specificity, positive predictive value and negative predictive value of antibody isotypes when comparing patients with RA versus non-RA patients (persistent non-RA and resolving)
| Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | |
|---|---|---|---|---|
| Anti-CCP | 47.5% (37.5% to 57.7%) | 98.2% (94.8% to 99.6%) | 94.1% (83.7% to 98.7%) | 75.6% (69.3% to 81.1%) |
| Rheum factor | ||||
| IgG | 55.5% (45.2% to 65.3%) | 92.2% (87.0% to 95.7%) | 81.2% (69.9% to 89.6%) | 77.4% (70.9% to 83.0%) |
| IgA | 33.6% (24.6% to 43.8%) | 91.0% (85.6% to 94.8%) | 69.4% (54.6% to 81.8%) | 69.4% (62.8% to 75.4%) |
| Anti-CitVimentin | ||||
| IgG | 56.4% (46.2% to 66.3%) | 83.2% (76.7% to 88.6%) | 67.1% (56.0% to 76.9%) | 76% (69.1% to 81.9%) |
| IgA | 43.6% (33.7% to 53.8%) | 73.1% (65.6% to 79.6%) | 49.4% (38.7% to 60.3%) | 68.2% (60.8% to 74.9%) |
| Anti-CarVimentin | ||||
| IgG | 34.7% (25.5% to 44.8%) | 94% (89.3% to 97.1%) | 77.8% (62.9% to 88.9%) | 70.4% (63.9% to 76.3%) |
| IgA | 16.8% (10.1% to 25.6%) | 88% (82.1% to 92.5%) | 45.9% (29.5% to 63.1%) | 63.6% (57.1% to 69.8%) |
| Anti-AcVimentin | ||||
| IgG | 36.6% (27.3% to 46.8%) | 86.2% (80.1% to 91.1%) | 61.7% (48.2% to 73.9%) | 69.2% (62.5% to 75.4%) |
| IgA | 35.6% (26.4% to 45.8%) | 64.7% (56.9% to 71.9%) | 37.9% (28.2% to 48.4%) | 62.4% (54.8% to 69.7%) |
AcVim, acetylated vimentin peptide; CarVim, carbamylated vimentin peptide; CitVim, citrullinated vimentin peptide; NPV, negative predictive value; PPV, positive predictive value; RA, rheumatoid arthritis.